Phuturdex › Diseases › Ependymoma
Drugs in development · updated 30 October 2026
Ependymoma: drugs in development
As of 30 October 2026 there are 37 active clinical trials (recruiting or ongoing, phases I–III) on 56 drugs for ependymoma. 18 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Indoximod | II | 2 | NCT04049669 |
| Tipifarnib | II | 2 | NCT04284774 |
| Ulixertinib | II | 2 | NCT03698994 |
| 5-ALA | II | 1 | NCT06678867 |
| ^1^1C-methionine | II | 1 | NCT02125786 |
| Antiemetics | II | 1 | NCT04743661 |
| Antipyretic | II | 1 | NCT04743661 |
| CobolimabTSR-022 | I–II | 1 | NCT06521567 |
| DNX-2401 | II | 1 | NCT07424092 |
| LuvometinibFCN-159 | II | 1 | NCT07713745 |
| Omburtamab I-131 | II | 1 | NCT04743661 |
| PLX038 | I–II | 1 | NCT06161519 |
| SamotolisibLY3023414 | II | 1 | NCT03155620 |
| SerplulimabHLX10, Hetronifly® | II | 1 | NCT07713745 |
| ONC206 | I | 2 | NCT04541082 |
| G207 | I | 1 | NCT03911388 |
| IL13Ralpha2-specific | I | 1 | NCT04661384 |
| Iopofosine I 131CLR 131 | I | 1 | NCT03478462 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II | 6 | NCT01356290 |
| EtoposideAvopef®, Etopophos Preservative Free® | I–II | 5 | NCT06485908 |
| TemozolomideTemodal, Temodar | II | 4 | NCT01356290 |
| Bevacizumabavastin, MVASI | II | 3 | NCT04374305 |
| SelumetinibAZD6244, Koselugo® | II | 3 | NCT07707947 |
| CelecoxibCelebrex Capsule, Elyxyb® | II | 2 | NCT01356290 |
| EnsartinibX-396, Ensatinib | II | 2 | NCT03213652 |
| ErdafitinibBalversa® | II | 2 | NCT03210714 |
| IrinotecanOnivyde, CPT-11 | II | 2 | NCT01356290 |
| IvosidenibAG-120, Tibsovo® | II | 2 | NCT03155620 |
| LarotrectinibBAY2757556, Vitrakvi® | II | 2 | NCT03155620 |
| LutatheraLutetium Lu 177 Dotatate, 177Lu-DOTATATE | I–II | 2 | NCT05278208 |
| OlaparibAZD2281, Lynparza® | I–II | 2 | NCT06607692 |
| SelpercatinibLOXO-292, Retevmo® | II | 2 | NCT04320888 |
| 18F-FDG^1^8F-fluorodeoxyglucose, Fludeoxyglucose F-18 | II | 1 | NCT02125786 |
Sorted by most advanced phase and number of active trials. Showing 15 of 38 drugs.
All 56 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Glandular and epithelial neoplasm 12 drugs
- Nerve tissue neoplasm 4 drugs
- Neuroectodermal tumor 3 drugs
- Neoplasm 671 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Neuroepithelial neoplasm 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D004806 “Ependymoma”. Prevalence: Orphanet.